Core Viewpoint - The announcement indicates a significant change in the ownership structure of Qidi Pharmaceutical, with Hunan Sailuxian acquiring 24.47% of the company's shares, leading to a change in control and potential impacts on corporate governance [1] Summary by Relevant Sections Ownership Change - Qidi Pharmaceutical announced that on August 6, it received an execution ruling from the Beijing Financial Court, transferring 58.607 million shares (24.47% of total shares) from Qidi Kefu to Hunan Sailuxian [1] - Following this transfer, Qidi Kefu will no longer hold any shares in Qidi Pharmaceutical, reducing its and its concerted action party, Huaqing Investment's total shareholding to 4.5445 million shares (1.90% of total shares) [1] Impact on Corporate Governance - The acquisition of a controlling stake by Hunan Sailuxian is expected to have a significant impact on the company's ownership structure and governance [1]

Core Viewpoint - The financial advisor, CITIC Securities, has verified the detailed equity change report of Tsinghua Unigroup Pharmaceutical Group Co., Ltd., confirming that the disclosed information is accurate, complete, and compliant with relevant laws and regulations [1][5][21]. Group 1: Overview of the Equity Change - The equity change involves the acquisition of 58,606,962 shares of Tsinghua Unigroup, representing 24.47% of the total share capital, making the acquirer the controlling shareholder [16][17]. - The acquisition was executed through a judicial auction, with the total payment amounting to 1,007.39 million yuan [21][22]. Group 2: Financial Status of the Acquirer - The acquirer, Hunan Sailoxian Management Consulting Partnership (Limited Partnership), was established on June 19, 2025, with a registered capital of 405.57 million yuan [5][6]. - The financial data of the acquirer shows total assets of 1,650.71 million yuan and total equity of 1,322.98 million yuan as of December 31, 2024 [13]. Group 3: Impact on Tsinghua Unigroup - Tsinghua Unigroup will maintain its independence as a listed company, with no plans to change its main business or make significant adjustments in the next 12 months [22][24]. - The acquirer has committed to avoiding any actions that would harm the interests of Tsinghua Unigroup and its minority shareholders [25][29]. Group 4: Compliance and Regulatory Aspects - The acquirer has adhered to all necessary legal procedures and obligations regarding the equity change, including the commitment to disclose any future changes in shareholding [16][22]. - There are no reported violations or legal issues concerning the acquirer in the past five years [14][15].

Core Viewpoint - The announcement by Qidi Pharmaceutical indicates a significant change in its shareholding structure due to a judicial auction, which will impact the company's control and governance [3]. Group 1: Financial Performance - For the year 2024, Qidi Pharmaceutical's revenue composition is as follows: Traditional Chinese medicine and health products account for 93.88%, while other products account for 6.12% [1]. Group 2: Shareholding Changes - On August 6, 2025, Qidi Pharmaceutical will transfer 58,606,962 shares from its controlling shareholder, Qidi Technology Service Co., Ltd., to Hunan Sailoxian Management Consulting Partnership, resulting in a decrease of Qidi Technology's shareholding from 26.37% to 1.90% [3]. - Hunan Sailoxian will acquire 58,606,962 shares, representing 24.47% of the total share capital of Qidi Pharmaceutical, marking a significant shift in ownership [3]. - This change in shareholding will not trigger a mandatory takeover bid but will lead to a change in control, significantly affecting the company's equity structure and governance [3].

Core Viewpoint - Tsinghua Unigroup (启迪药业) announced a significant change in its shareholding structure due to a judicial auction, resulting in a shift of control from its major shareholder, Tsinghua Technology Service Co., Ltd. (启迪科服), to Hunan Sailuxian Management Consulting Partnership (湖南赛乐仙) [1] Shareholding Changes - Tsinghua Technology Service Co., Ltd. will transfer 58,606,962 shares of Tsinghua Unigroup to Hunan Sailuxian, leading to a decrease in its shareholding from 63,151,413 shares to 4,544,451 shares [1] - The ownership percentage of Tsinghua Technology Service will drop from 26.37% to 1.90%, while Hunan Sailuxian will acquire 24.47% of the total shares, marking a significant entry into the company's equity structure [1] Impact on Company Control - The transfer of shares will result in a change of control over Tsinghua Unigroup, which is expected to have a major impact on the company's governance and overall shareholding structure [1]

Core Viewpoint - The announcement indicates a significant change in the ownership structure of Qidi Pharmaceutical, with Hunan Sailuxian acquiring a substantial stake, leading to a shift in control and governance of the company [1] Group 1: Ownership Changes - Qidi Pharmaceutical received a court ruling that mandates the transfer of 58.607 million shares from Qidi Kefu to Hunan Sailuxian [1] - Following this transfer, Qidi Kefu will no longer hold any shares in Qidi Pharmaceutical, and its associated entity, Huqing Investment, will see its shareholding drop from 63.1514 million shares to 4.5445 million shares [1] - Hunan Sailuxian will hold 58.607 million shares, representing 24.47% of the total share capital of Qidi Pharmaceutical after the transfer [1] Group 2: Impact on Control and Governance - The change in ownership will result in a shift in control of Qidi Pharmaceutical, which is expected to have a significant impact on the company's equity structure and governance [1] - The ownership change does not trigger a mandatory tender offer, indicating that the acquisition process will not require additional offers to other shareholders [1]

启迪药业集团股份公司 二、信息披露义务人签署本报告书已获得必要的授权和批准，其行为亦不 违反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 详式权益变动报告书 上市公司名称：启迪药业集团股份公司 股票上市地点：深圳证券交易所 股票简称：启迪药业 股票代码：000590.SZ 信息披露义务人：湖南赛乐仙管理咨询服务合伙企业（有限合伙） 注册地址：长沙市开福区青竹湖街道青竹湖路 29 号长沙金霞海关保税物流 投资建设有限公司商务写字楼 1607 房 通讯地址：长沙市开福区青竹湖街道青竹湖路 29 号长沙金霞海关保税物流 投资建设有限公司商务写字楼 1607 房 股份变动性质：股份增加（司法拍卖） 签署日期：2025 年 8 月 启迪药业集团股份有限公司详式权益变动报告书 信息披露义务人声明 一、本报告书系根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》及相关法律、法规和部门规章有关规定编制。 | 第一节 | 释 义 3 | ...

启迪药业集团股份公司 关于控股股东所持公司股份被司法拍卖暨控制权拟发生变更的 证券代码：000590 证券简称：启迪药业 公告编号：2025-026 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、2025 年 8 月 6 日，启迪药业集团股份公司（以下简称"公司"或"启 迪药业"）收到湖南赛乐仙管理咨询服务合伙企业（有限合伙）（以下简称 "湖南赛乐仙"）送达的北京金融法院《执行裁定书》【(2024)京 74 执 1019 号】，裁定将被执行人启迪科技服务有限公司（以下简称"启迪科服"）持有 的启迪药业 58,606,962 股股票过户至买受人湖南赛乐仙名下，买受人可持裁定 书到相关登记管理机构办理过户登记手续。 2、本次权益变动系公司控股股东启迪科服所持有的公司 58,606,962 股股票 被司法拍卖所致。本次权益变动后，启迪科服将不再持有公司股票，启迪科服及 其一致行动人北京华清投资有限公司（以下简称"华清投资"）持有的公司股票 总数从 63,151,413 股下降为 4,544,451 股，占公司总股本的比例从 26.3 ...

中信证券股份有限公司 关于 启迪药业集团股份公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 二〇二五年八月 中信证券股份有限公司关于启迪药业集团股份有限公司详式权益变动报告书之财务顾问核查意见 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购 管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动 报告书》及《公开发行证券的公司信息披露内容与格式准则第16号——上市公司 收购报告书》等法律法规和规范性文件的规定，中信证券股份有限公司（以下简 称"本财务顾问"）按照行业公认的业务标准、道德规范，本着诚实信用、勤勉 尽责的精神，对本次权益变动的相关情况和资料进行了核查，对信息披露义务人 出具的《启迪药业集团股份有限公司详式权益变动报告书》所披露的内容出具核 查意见，以供投资者和有关各方参考。 为此，本财务顾问特作出以下声明： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《启迪药业集团股份有限公司详式权益变动报告书》进行了核查，确信披露文件 内容与格式符合规定，并有充分理由确信所发表的专业意见与信息披露义务人披 露的文件内容不存在实质性差 ...

Market Overview - The Shanghai Composite Index closed at 3602.13 points, with a gain of 0.53% [1] - The total trading volume of A-shares reached 10185.93 billion yuan [1] Technical Analysis - A total of 29 A-shares experienced a death cross between the 5-day and 10-day moving averages today [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Xiongdi Technology: 5-day MA down by 1.70% from the 10-day MA [1] - Sanwei Xinan: 5-day MA down by 1.11% from the 10-day MA [1] - Jinling Sports: 5-day MA down by 1.10% from the 10-day MA [1] Individual Stock Performance - Xiongdi Technology (300546): Today's change -0.23%, latest price 26.47 yuan, 5-day MA 27.31 yuan, 10-day MA 27.78 yuan [1] - Sanwei Xinan (688489): Today's change -0.80%, latest price 39.85 yuan, 5-day MA 40.62 yuan, 10-day MA 41.08 yuan [1] - Jinling Sports (300651): Today's change +0.89%, latest price 21.48 yuan, 5-day MA 23.82 yuan, 10-day MA 24.09 yuan [1] - Other notable stocks include: - Huanrui Century (000892): Today's change -0.86%, latest price 4.59 yuan [1] - Junshi Biological (688180): Today's change +0.45%, latest price 37.83 yuan [1] - Yihau New Materials (301176): Today's change -1.64%, latest price 30.65 yuan [1] Additional Stock Data - Other stocks with notable performance include: - Guanghe Technology (001389): Today's change -2.81%, latest price 62.20 yuan [1] - Kehua Data (002335): Today's change -2.13%, latest price 41.44 yuan [1] - ST Ruihe (002620): Today's change +0.26%, latest price 3.84 yuan [1] - The performance of these stocks indicates a mixed sentiment in the market, with some stocks showing declines while others remain stable or increase slightly [1][2]

Market Overview - The Chinese medicine sector rose by 1.0% on July 29, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] Top Gainers in Chinese Medicine Sector - Foci Pharmaceutical (002644) closed at 10.69, up 9.98% with a trading volume of 841,300 shares and a turnover of 876 million yuan [1] - Zhongsheng Pharmaceutical (002317) also rose by 9.98% to 19.73, with a trading volume of 1,168,400 shares and a turnover of 2.26 billion yuan [1] - Other notable gainers include: - Zhendong Pharmaceutical (300158) up 6.66% to 7.69 [1] - Huasen Pharmaceutical (002907) up 6.50% to 18.51 [1] - Kangjia Pharmaceutical (600557) up 5.61% to 16.58 [1] Top Losers in Chinese Medicine Sector - Qidi Pharmaceutical (000590) fell by 2.65% to 12.13, with a trading volume of 134,500 shares and a turnover of 163 million yuan [2] - Zhenbaodao (603567) decreased by 2.21% to 12.40, with a trading volume of 182,700 shares and a turnover of 227 million yuan [2] - Other notable losers include: - Yunnan Baiyao (000538) down 1.20% to 55.82 [2] - Kangmei Pharmaceutical (600518) down 0.94% to 2.10 [2] Capital Flow Analysis - The Chinese medicine sector saw a net inflow of 798 million yuan from institutional investors, while retail investors experienced a net outflow of 625 million yuan [2][3] - Notable net inflows from institutional investors include: - Zhongsheng Pharmaceutical (002317) with a net inflow of 308 million yuan [3] - Zhendong Pharmaceutical (300158) with a net inflow of 96.32 million yuan [3] - Conversely, significant net outflows from retail investors were observed in: - Zhongsheng Pharmaceutical (002317) with a net outflow of 98.88 million yuan [3] - Zhendong Pharmaceutical (300158) with a net outflow of 65.62 million yuan [3]